Truncated L1 protein of human papillomavirus type 52
US9499591B2 · kind B2 · utility
0Cited by
2References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 1, 2011 |
| Grant date | Nov 22, 2016 |
| Priority date | — |
| Expiry date | Jul 5, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/20051
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a truncated L1 protein of Human Papillomavirus (HPV) Type 52 which, compared to a wild type HPV52 L1 protein, is truncated by 27-42 amino acids at the N-terminal. Also provided are a coding sequence of the truncated HPV52 L1 protein, a virus-like particle (VLP) comprising the protein, and a method of preparing the protein and the VLP using an E. coli expression system. The truncated HPV52 L1 protein and an assembled VLP can be used to prevent an HPV52 infection and a disease caused by HPV52 infection, such as cervical cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.